# LPA2 antagonist 2

| | |
|---|---|
| **Cat. No.:** | HY-113973 |
| **CAS No.:** | 36840-10-5 |
| **Molecular Formula:** | $C_{20}H_{16}N_2O_6$ |
| **Molecular Weight:** | 380.35 |
| **Target:** | LPL Receptor |
| **Pathway:** | GPCR/G Protein |
| **Storage:** | Powder -20°C 3 years<br>4°C 2 years<br>In solvent -80°C 2 years<br>-20°C 1 year |



## SOLVENT & SOLUBILITY

**In Vitro**

DMSO : 83.33 mg/mL (219.09 mM; Need ultrasonic)

| Preparing Stock Solutions | Solvent / Mass / Concentration | 1 mg | 5 mg | 10 mg |
|---|---|---|---|---|
| | 1 mM | 2.6292 mL | 13.1458 mL | 26.2916 mL |
| | 5 mM | 0.5258 mL | 2.6292 mL | 5.2583 mL |
| | 10 mM | 0.2629 mL | 1.3146 mL | 2.6292 mL |

Please refer to the solubility information to select the appropriate solvent.

## BIOLOGICAL ACTIVITY

**Description**

LPA2 antagonist 2 (H2L 5226501) is a selective $LPA_2$ antagonist with an $IC_{50}$ of 28.3 nM and a $K_i$ of 21.1 nM. LPA2 antagonist 2 is >480-fold more selective than $LPA_3$ ($IC_{50}$ of 13.85 μM)[1].

**$IC_{50}$ & Target**

IC50: 28.3 nM ($LPA_2$); 13.85 μM ($LPA_3$)[1]

**In Vitro**

Lysophosphatidic acid (LPA) is a phospholipid mediator that elicits a host of biological effects including cell proliferation, survival, motility and differentiation. LPA has been shown to regulate cancer cell invasion, metastasis, and resistance to both chemotherapeutics and radiation. LPA2 antagonist 2 (H2L 5226501) inhibits $LPA_1$ with an Imax of 59.0% at 30 μM[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Fells JI, et al. Identification of non-lipid LPA3 antagonists by virtual screening. Bioorg Med Chem. 2008 Jun 1;16(11):6207-17.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA